Related references
Note: Only part of the references are listed.
Article
Immunology
Jiankai Liu et al.
Summary: This study evaluated the efficacy and safety of a SARS-CoV-2 inactivated vaccine. The results showed that two doses of the vaccine induced a robust immune response and had a good safety profile. The third dose given 28 days after the second dose had limited boosting antibody response.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Infectious Diseases
Gang Zeng et al.
Summary: The study showed that a two-dose schedule of CoronaVac generated good immune response in adults, and a third dose given 8 months after the second dose effectively recalled specific immune responses to SARS-CoV-2, leading to a remarkable increase in antibody concentration. This indicates that the two-dose schedule provides good immune memory, and a primary third dose given 2 months after the second dose induced slightly higher antibody titres than the primary two doses.
LANCET INFECTIOUS DISEASES
(2022)
Article
Biochemistry & Molecular Biology
Jingxin Li et al.
Summary: The study suggests that additional COVID-19 vaccine doses may be needed for individuals who initially received CoronaVac. Heterologous boosting with Convidecia, a recombinant adenovirus type 5 (AD5)-vectored vaccine, was found to be safe and more immunogenic than homologous boosting with CoronaVac in adults previously vaccinated with CoronaVac.
Article
Infectious Diseases
Ivana Knezevic et al.
Summary: This article introduces the WHO Antibody Standards for SARS-CoV-2 and focuses on their application in evaluating the immune response to COVID-19 vaccines. The use of these standards facilitates comparison of assay results conducted in different countries and contributes to a better understanding of the immune response.
Article
Infectious Diseases
Denis Saure et al.
Summary: The study in Chile found that individuals who received the CoronaVac vaccine had a lower IgG seropositivity compared to those who received the BNT162b2 vaccine. Over time, the IgG seropositivity for CoronaVac recipients declined, while those who received BNT162b2 maintained high levels of IgG positivity. Further monitoring of IgG levels will help in evaluating vaccine effectiveness and exploring potential adjustments to vaccination strategies in the future.
LANCET INFECTIOUS DISEASES
(2022)
Article
Critical Care Medicine
Jing-Xin Li et al.
Summary: In a randomized controlled trial, researchers found that heterologous boost immunization with an orally administered aerosolized adenovirus-based COVID-19 vaccine is safe and highly immunogenic in adults previously primed with two doses of an inactivated COVID-19 vaccine.
LANCET RESPIRATORY MEDICINE
(2022)
Article
Public, Environmental & Occupational Health
Dan Wu et al.
Summary: In an outbreak from a hospital setting, completion of primary vaccination with inactivated COVID-19 vaccines reduces the risk of symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the Delta variant. Partial vaccination is ineffective, and completion of two doses of the primary vaccination is necessary for protection from Delta.
Article
Infectious Diseases
Shengli Xia et al.
Summary: The inactivated SARS-CoV-2 vaccine, BBIBP-CorV, demonstrated safety and immunogenicity in two age groups. Humoral responses against SARS-CoV-2 were induced in all vaccine recipients by day 42. A two-dose immunisation with 4 mu g vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralising antibody titres compared to other dosing schedules.
LANCET INFECTIOUS DISEASES
(2021)
Letter
Medicine, General & Internal
Alicia T. Widge et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Sara Y. Tartof et al.
Summary: This study aimed to assess the overall and variant-specific effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19-related hospital admissions among members of a healthcare system in California. The effectiveness of the vaccine remained high against hospital admissions even up to 6 months after full vaccination, despite a decline in effectiveness against SARS-CoV-2 infections over time, which was likely due to waning immunity rather than the delta variant escaping vaccine protection.
News Item
Multidisciplinary Sciences
Smriti Mallapaty
Article
Biochemistry & Molecular Biology
Shuo Feng et al.
Summary: Defined levels of SARS-CoV-2-specific binding and neutralizing antibodies elicited by the COVID-19 vaccine were identified as correlates of protection against symptomatic infection. Higher levels of immune markers were correlated with a reduced risk of symptomatic infection. The data can be used to extrapolate efficacy estimates to new populations.
Article
Medicine, General & Internal
Einav G. Levin et al.
Summary: A study in Israel revealed that waning immunity after receiving two doses of the BNT162b2 vaccine led to an increase in the incidence of SARS-CoV-2 infection. Levels of spike-binding IgG and neutralizing antibodies decreased more significantly in men, individuals aged 65 or older, and immunosuppressed individuals in a longitudinal study involving nearly 4000 healthcare workers.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Infectious Diseases
Yanjun Zhang et al.
Summary: This study investigated the safety, tolerability, and immunogenicity of the COVID-19 vaccine candidate CoronaVac, and found that the 3 μg dose showed higher seroconversion rates in the phase 2 trial.
LANCET INFECTIOUS DISEASES
(2021)
Editorial Material
Medicine, General & Internal
Youchun Wang
Article
Microbiology
Minjeong Nam et al.
Summary: Both BNT162b2 and ChAdOx1 nCoV-19 vaccines elicited robust humoral responses, with strong correlations observed between sCOVG, CoV-2 IgG II, and cPASS. sCOVG and CoV-2 IgG II could potentially predict the presence of neutralizing antibodies against SARS-CoV-2.
MICROBIOLOGY SPECTRUM
(2021)
Article
Biochemistry & Molecular Biology
David S. Khoury et al.
Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.
Letter
Medicine, General & Internal
Guo-Lin Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Nicole Doria-Rose et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Endocrinology & Metabolism
Shelly Soffer et al.
Summary: Obesity is associated with severe COVID-19 infection, and disease severity is linked to higher COVID-19 antibody titers. The study compared COVID-19 antibody responses between patients with and without obesity. The findings suggest that obesity is associated with higher COVID-19 antibody titers, which has implications for understanding the role of obesity in COVID-19 severity.
Letter
Medicine, General & Internal
Timothy A. Bates et al.
Summary: This study investigates the correlation between age and neutralizing antibody levels against the SARS-CoV-2 USA-WA1/2020 strain and the P.1 variant after receiving 2 doses of the BNT162b2 vaccine.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Nawal Al Kaabi et al.
Summary: This interim analysis of an ongoing randomized trial in the UAE and Bahrain evaluated the efficacy of two inactivated COVID-19 vaccines in preventing symptomatic cases and adverse events in healthy adults. The study found that both vaccines significantly reduced the risk of symptomatic COVID-19 compared to the control group, with efficacy rates of 72.8% and 78.1%. Serious adverse events were rare across all groups.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Letter
Medicine, General & Internal
Madhumita Shrotri et al.
Editorial Material
Infectious Diseases
Prerak Juthani et al.
LANCET INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
Alejandro Jara et al.
Summary: A study in Chile involving 10.2 million participants assessed the effectiveness of an inactivated SARS-CoV-2 vaccine developed in China. Fully immunized individuals had vaccine effectiveness of 65.9% for preventing Covid-19 and 87.5% for preventing hospitalization, 90.3% for preventing ICU admission, and 86.3% for preventing death.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Dan H. Barouch et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Moriah Bergwerk et al.
Summary: Among fully vaccinated health care workers, breakthrough infections with SARS-CoV-2 were correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
S. J. Thomas et al.
Summary: BNT162b2 vaccine remains highly effective and safe over the course of 6 months post-vaccination, with efficacy rates ranging from 86% to 100% across different demographics and risk factors for Covid-19. The vaccine also shows a high efficacy against severe disease, with particularly promising results observed in South Africa against the B.1.351 variant.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Amarendra Pegu et al.
Summary: The study assessed the impact of SARS-CoV-2 variants on antibody responses induced by the mRNA vaccine over 7 months, showing that most individuals maintained binding and functional antibodies against variants, with B.1.351 having the lowest antibody recognition.
Article
Critical Care Medicine
Yaniv Lustig et al.
Summary: The study assessed early antibody responses after Pfizer-BioNTech BNT162b2 COVID-19 vaccine in Israeli healthcare workers. Results showed that 77% of participants had positive IgG response at week 3 after the first vaccine dose, with lower responses in older and immunosuppressed individuals. Timely second dose vaccinations are particularly important for these populations to enhance antibody responses and reduce breakthrough infections.
LANCET RESPIRATORY MEDICINE
(2021)
Article
Health Care Sciences & Services
Paul Naaber et al.
Summary: The study found that antibody levels declined at 12 weeks and 6 months after receiving two doses of BNT162b2 vaccine, with Spike antibody levels at 6 months being similar to those in individuals who received one dose or had recovered from COVID-19. Most individuals developed Spike-specific memory T cell responses, which were lower in those with higher T cell immunosenescence. Antibody response was negatively correlated with age and positively correlated with the total score of vaccination side effects.
LANCET REGIONAL HEALTH-EUROPE
(2021)
Article
Public, Environmental & Occupational Health
Shiwei Liu et al.
Summary: This report shows that the first case of COVID-19 in Nangong City was infected from a confirmed case in Shijiazhuang City, leading to 76 local cases. The main routes of transmission were family clusters, intra-unit transmission, and nosocomial transmission. The study highlights new techniques for rapidly tracing cases and identifying COVID-19 transmission chains.
Article
Medicine, General & Internal
Hong-Xing Pan et al.
Summary: This study reported the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, KCONVAC, in healthy adults. The vaccine demonstrated good tolerability and induced robust immune responses in both phase 1 and phase 2 trials.
CHINESE MEDICAL JOURNAL
(2021)
Review
Endocrinology & Metabolism
Yi Huang et al.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2020)
